Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BiomX ( (PHGE) ) just unveiled an announcement.
On July 8, 2025, BiomX Inc. announced the publication of new efficacy data from the Phase 1b/2a trial of BX004 in cystic fibrosis patients in Nature Communications. The study demonstrated a significant reduction in Pseudomonas aeruginosa bacteria with no emergent resistance, validating BiomX’s phage therapy platform. The company is advancing to a Phase 2b trial, with results expected in Q1 2026, potentially strengthening its position in treating chronic infections where traditional antibiotics have failed.
The most recent analyst rating on (PHGE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX is a clinical-stage company specializing in the development of natural and engineered phage cocktails and personalized phage treatments aimed at targeting and eliminating harmful bacteria to treat chronic diseases with significant unmet needs. The company utilizes its BOLT platform to identify and validate bacterial targets and customize phage compositions against these targets.
Average Trading Volume: 148,085
Technical Sentiment Signal: Sell
Current Market Cap: $11.52M
Learn more about PHGE stock on TipRanks’ Stock Analysis page.